Taking these together, the colchicine users were associated with the optimal counterbalance effect on the NLRP3 inflammasome, thus the young male patients in the colchicine users were associated with the lower risk of the colorectal cancer (negative effect on the aHR) in a later course of the chronic colitis even with the higher frequency of the comorbidities (Tables 4, 5) [48, 49]. The gene discussed is NLRP3; the disease is Chronic colitis.